Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study

Overview

Journal Front Pharmacol

Date 2020 Sep 25

PMID 32973503

Citations 2

Authors

Rongrong Wang

Weili Wang

Kuifen Ma

Xin Duan

Fangfang Wang

Mingzhu Huang

Wei Zhang

Tingbo Liang

Affiliations

Soon will be listed here.

Abstract

Objective: High variabilities in tacrolimus (TAC) exposure are still problems that confuse physicians. TAC trough levels (TAC C) fluctuated considerably after endoscopic retrograde cholangiopancreatography (ERCP) treatment in several liver transplant (LT) patients. We aimed to investigate the variation regularity of TAC C post-ERCP and related factors.

Methods: This study was a retrospective, observational study conducted at the First Affiliated Hospital of Zhejiang University in China. From October 2017 to January 2019, 26 LT patients that received ERCP were included (73 TAC C measures). The absolute difference and the variation extent in TAC C pre- and post-ERCP were analyzed. Patients were divided into mild and obvious variation groups, and the differences were compared.

Results: The TAC C in LT patients significantly increased in the first three days post-ERCP (<0.05) and increased by more than 20% in 18 out of 26 (69.2%) patients. The mean extent of variation in TAC C was 45.1% (95% confidence interval [CI]: 28.3-81.3%) and 31.4% (95% CI: 9.7-53.1%) on days 1 and 3 post-ERCP, respectively. The increasing TAC C gradually returned to baseline within a week (>0.05). The daily TAC dose and total bile acid (TBA) level were significantly higher (<0.05) in patients with obvious variation in TAC C. The differences in other demographics, clinical characteristics, variation in laboratory data, and serum amylase levels between the two groups were not significant.

Conclusion: The TAC C significantly increased in LT patients during the first three days after ERCP, and the level returned to baseline within a week. The daily TAC dose and TBA levels may be related to this increase. Frequent drug concentration monitoring should be executed in the early phase post-ERCP, especially in patients with related factors.

Citing Articles

Tacrolimus for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: a potential new target of old drug?.

Jeong S Clin Endosc. 2022; 55(5):628-629.

PMID: 36031763 PMC: 9539293. DOI: 10.5946/ce.2022.188.

Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?.

Chavant A, Fonrose X, Gautier-Veyret E, Hilleret M, Roustit M, Stanke-Labesque F Pharmaceutics. 2021; 13(11).

PMID: 34834375 PMC: 8623792. DOI: 10.3390/pharmaceutics13111960.

References

Rayar M, Tron C, Jezequel C, Beaurepaire J, Petitcollin A, Houssel-Debry P . High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. Transplantation. 2018; 102(3):e108-e114. DOI: 10.1097/TP.0000000000002052. View

. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2015; 64(2):433-485. DOI: 10.1016/j.jhep.2015.10.006. View

Charlton M, Levitsky J, Aqel B, OGrady J, Hemibach J, Rinella M . International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018; 102(5):727-743. DOI: 10.1097/TP.0000000000002147. View

van der Veer M, Nangrahary N, Hesselink D, Erler N, Metselaar H, van Gelder T . High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation. Transplantation. 2019; 103(11):2329-2337. DOI: 10.1097/TP.0000000000002680. View

Ericzon B, Eusufzai S, Soderdahl G, Duraj F, Einarsson K, Angelin B . Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. Transplantation. 1997; 63(1):74-80. DOI: 10.1097/00007890-199701150-00014. View

Ferreira L, Topazian M, Harmsen W, Zinsmeister A, Baron T . Dietary approaches following endoscopic retrograde cholangiopancreatography: A survey of selected endoscopists. World J Gastrointest Endosc. 2010; 2(12):397-403. PMC: 3010470. DOI: 10.4253/wjge.v2.i12.397. View

Watt K, Charlton M . Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010; 53(1):199-206. DOI: 10.1016/j.jhep.2010.01.040. View

Staatz C, Tett S . Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. Eur J Clin Pharmacol. 2002; 58(9):597-605. DOI: 10.1007/s00228-002-0517-7. View

Tringali A, Barbaro F, Pizzicannella M, Boskoski I, Familiari P, Perri V . Endoscopic management with multiple plastic stents of anastomotic biliary stricture following liver transplantation: long-term results. Endoscopy. 2016; 48(6):546-51. DOI: 10.1055/s-0042-100277. View

10.

Kalt D . Tacrolimus: A Review of Laboratory Detection Methods and Indications for Use. Lab Med. 2017; 48(4):e62-e65. DOI: 10.1093/labmed/lmx056. View

11.

Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink D, Langman L . Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit. 2019; 41(3):261-307. DOI: 10.1097/FTD.0000000000000640. View

12.

Dai S, Goldberg D, Agarwal A, Ma G, Yam C, Ahmad N . Endoscopic Therapy is Effective for Recurrent Anastomotic Biliary Strictures after Orthotopic Liver Transplantation. Ann Hepatol. 2017; 16(6):924-931. DOI: 10.5604/01.3001.0010.5284. View

13.

Defrancq C, De Wilde N, Raes A, Van Biervliet S, Velde S, Van Winckel M . Intra-patient variability in tacrolimus exposure in pediatric liver transplant recipients: Evolution, risk factors, and impact on patient outcomes. Pediatr Transplant. 2019; 23(3):e13388. DOI: 10.1111/petr.13388. View

14.

Dawson P, Lan T, Rao A . Bile acid transporters. J Lipid Res. 2009; 50(12):2340-57. PMC: 2781307. DOI: 10.1194/jlr.R900012-JLR200. View

15.

Campagne O, Mager D, Tornatore K . Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?. J Clin Pharmacol. 2018; 59(3):309-325. PMC: 7395655. DOI: 10.1002/jcph.1325. View

16.

Martins F, de Paulo G, Contini M, Ferrari A . Metal versus plastic stents for anastomotic biliary strictures after liver transplantation: a randomized controlled trial. Gastrointest Endosc. 2017; 87(1):131.e1-131.e13. DOI: 10.1016/j.gie.2017.04.013. View

17.

Park C, Jung J, Hyun B, Kan H, Lee J, Kae S . Safety and efficacy of early feeding based on clinical assessment at 4 hours after ERCP: a prospective randomized controlled trial. Gastrointest Endosc. 2017; 87(4):1040-1049.e1. DOI: 10.1016/j.gie.2017.09.021. View

18.

Shuker N, van Gelder T, Hesselink D . Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando). 2015; 29(2):78-84. DOI: 10.1016/j.trre.2015.01.002. View

19.

Kuypers D . Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. Clin Pharmacol Ther. 2019; 107(2):347-358. DOI: 10.1002/cpt.1618. View

20.

McCashland T, Donovan J, Amelsberg A, Rossi S, Hofmann A, Shaw Jr B . Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK 506. Hepatology. 1994; 19(6):1381-9. View